Market Overview

UPDATE: Morgan Stanley Initiates Infinity Pharmaceuticals at Overweight on Blood Cancer Drug Data

Related INFI
UPDATE: Credit Suisse Downgrades Infinity Pharmaceuticals on Limited Clinical News in 2014
Benzinga's Top Downgrades

Morgan Stanley initiated Infinity Pharmaceuticals (NASDAQ: INFI) with an Overweight rating and a $47.00 price target.

Morgan Stanley noted, "Infinity's wholly-owned early stage IPI-145 for blood cancers has shown positive early data and is on track to figure significantly in an emerging BCR drug class with multi-billion dollar potential. 2013 holds multiple catalysts to further validate IPI-145's efficacy/safety."

Infinity Pharmaceuticals closed at $35.20 on Friday.

Posted-In: Morgan StanleyAnalyst Color Initiation Analyst Ratings

 

Most Popular

Related Articles (INFI)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free